Logo
x

Search

Subscribe Now

Eccogene

Eccogene Reports the First Patient Dosing with ECC5004/AZD5004 in P-IIb Trial of Obesity and T2D, Triggering $60M Milestone from AstraZeneca

Eccogene Reports the First Patient Dosing with ECC5004/AZD5004 in P-IIb Trial of Obesity and T2D, Triggering $60M Milestone from A...

  • October 23, 2024
Eccogene Enters into a Collaboration Agreement with AstraZeneca to Develop and Commercialize ECC5004 for Cardiometabolic Diseases

Eccogene Enters into a Collaboration Agreement with AstraZeneca to Develop and Commercialize ECC5004 for Cardiometabolic Diseases

  • November 9, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.